(Redirected from Butabarbital)
Barbiturates is a group of sedatives that reduce activity in the brain; are habit-forming and are possibly fatal when taken with alcohol.
Information about Barbiturates
Barbiturates are structurally related compounds with sedative and hypnotic activities, some of which (phenobarbital and mephobarital) are also used as anticonvulsants.
Liver safety of Barbiturates
Phenobarbital has been clearly linked to cases of idiosyncratic acute liver injury, resembling the immunoallergic hepatotoxicity of other aromatic anticonvulsants such as phenytoin and carbamazepine. In contrast, the other conventional sedative barbiturates have not been linked to serum enzyme elevations during therapy and clinically apparent acute liver injury due to the sedative barbiturates is extremely rare, if it occurs at all. == Mechanism of action of Barbiturates == Barbiturates are a family of compounds that have sedative and hypnotic activities and act as nonselective central nervous system (CNS) depressants. Phenobarbital has also been used as an anticonvulsant, acting by suppression of spread of seizure activity by enhancing the effect of gamma aminobutyric acid (GABA). Phenobarbital (fee" noe bar' bi tal) has been linked to instances of acute liver injury and is discussed separately as an anticonvulsant.
Clinical use of Barbiturates
Amobarbital, butabarbital, pentobarbital and secobarbital are used as sedatives and hypnotics and not as anticonvulsants. These and several other barbiturates were introduced into medical use in the United States in the 1950s as sedatives, hypnotics (short term treatment of insomnia) and preanesthetic agents. They are now rarely used, having been largely replaced by more effective and better tolerated sedatives and hypnotics such as the benzodiazepines and benzodiazepine receptor agonists. Amobarbital (am" oh bar' bi tal) and butabarbital (bue' ta bar' bi tal) are currently available, but only as solutions for parenteral administration, being used largely as preanesthetic agents. Secobarbital is available as a 100 mg capsule generically and under the brand name Seconal. Pentobarbital is no longer available in the United States. Current indications for the barbiturates include short term treatment of insomnia and as a preanesthetic agent.
Dosage and administration for Barbiturates
The recommended dose of secobarbital in adults is 100 mg at bedtime or 200 to 300 mg 1 to 2 hours before surgery. Barbiturates that are no longer available in the United States include butalbital, mephobarbital, methohexital and pentobarbital. Secobarbital is classified as a Schedule II substance, indicating that it has definite potential for physical and psychological dependence and abuse. Frequent side effects include drowsiness, sedation, hypotension, nausea, headache and skin rash. The halogenated inhalational anesthetics have been linked to idiosyncratic liver injury for more than 50 years.
Mechanism of action of Barbiturates
These agents induce anesthesia by blocking CNS neurotransmission, although the exact mechanism of action is unknown. They are currently the most commonly used inhalational anesthetics in surgery.
FDA approval information for Barbiturates
In the United States, the five halogenated anesthetics in current use are halothane, isoflurane, enflurane, desflurane, and sevoflurane. Halothane is now rarely used outside of pediatrics because of its potential to cause idiosyncratic severe liver injury, which is rare in children. The classic form of anesthetic induced liver injury was associated with halothane, which was introduced into practice in 1956 and rapidly became the most commonly used agent for general anesthesia. Within a few years of its introduction. However, case reports of liver injury possibly due to halothane began to appear. There was initially great resistance to acceptance of the hepatotoxicity of halothane, largely because of its excellent safety record in other respects and the rarity of the hepatic reaction. Eventually, however, the potential hepatotoxicity of halothane became quite clear. By the 1970s, halothane had become the most common cause of idiosyncratic, drug induced acute liver failure and more than 1000 cases of clinically apparent liver injury had been described in the literature. Furthermore, a reasonable mechanism of hepatic injury by halothane was delineated based upon its extensive metabolism (oxidation) by the major drug metabolizing enzyme system of the liver, specifically the cytochrome P450, CYP 2E1.
The metabolism of halothane to a trifluoroacetylated reactive intermediate with subsequent binding to intrahepatic cytosolic proteins was believed to create an antigenic molecule capable of inducing allergic and cytotoxic reactions. This proposed mechanism also matched the allergic, clinical features of halothane hepatitis, marked by a typical incubation period of 7 days after anesthesia, accompanied often by fever, rash, arthralgias and eosinophilia and recurring with reexposure in an accelerated and often more severe form. Thus, the overall rate of occurrence of significant liver injury after halothane was estimated at 1 per 15,000 initial exposures, and probably 1 per 1000 repeated exposures, particularly if the reexposure was within 28 days. Having become the most common drug induced cause of acute liver failure in the United States and most of the world, halothane subsequently became less commonly used and is rarely employed currently. Other halogenated anesthetics have been introduced and become the major agents currently in use in the United States, including enflurane (1972), isoflurane (1981), desflurane (1993) and sevoflurane (1995). These agents have the theoretical advantage of less metabolism by the CYP 2E1 system (20% by halothane compared to 3% by sevoflurane, 2.4% by enflurane, 0.2% by isoflurane, and 0.01% by desflurane). Nevertheless, rare instances of acute liver injury have been reported with all agents.
Furthermore, the pattern of injury described with the newer halogenated anesthetics has resembled that of halothane hepatitis, and trifluoroacetyl adducts have been identified in liver tissue and antibodies to be the adducts in serum of patients with hepatic injury from these other agents. Nevertheless, anesthetic induced acute liver failure is now rare and no longer ranked among the more common causes of drug induced liver disease or acute liver failure. The various structures of the halogenated anesthetics are shown below. Each agent is discussed separately with individual clinical cases and references.